MedTrace Logo

Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema

NCT02096874 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-12-03

No results posted yet for this study

Summary

Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.

Conditions

Interventions

DRUG

Bevacizumab

Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month

Sponsors & Collaborators

  • King Khaled Eye Specialist Hospital

    lead OTHER_GOV

Principal Investigators

  • Saba al Rashaed, MD · King Khaled Eye Specialist Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-12-31
Completion
2015-06-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02096874 on ClinicalTrials.gov